Adenosine A2A Receptor Antagonists as Positron Emission Tomography (PET) Tracers

Author(s): S. Khanapur, A. van Waarde, K. Ishiwata, K. L. Leenders, R. A.J.O. Dierckx, P. H. Elsinga

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 3 , 2014

Become EABM
Become Reviewer
Call for Editor


The adenosine A2A receptor (A2AR) is highly concentrated in the striatum, and a therapeutic target for Parkinson’s disorder (PD) and Huntington’s disease. High affinity and selective radiolabeled A2AR antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A2A antagonists non-invasively in the brain. However, till date no complete review on A2AR PET ligands is available. The present article has been therefore focused on available PET tracers for A2AR and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A2ARs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A2AR for PD has also been presented.

Keywords: Adenosine A2A receptor, Parkinson’s disorder, positron emission tomography (PET), xanthine ligands, nonxanthine ligands, SCH442416, TMSX, 6-OHDA PD model.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 16 December, 2013
Page: [312 - 328]
Pages: 17
DOI: 10.2174/09298673113206660265
Price: $65

Article Metrics

PDF: 51